American Heart Journal
Volume 159, Issue 3 , Pages 354-360 , March 2010

Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction

  • Monica Taljaard, PhD

      Affiliations

    • Clinical Epidemiology Program, Ottawa Hospital Research Institute
    • Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada
    • Corresponding Author InformationReprint requests: Monica Taljaard, PhD, Ottawa Hospital Research Institute Clinical Epidemiology Program Ottawa Hospital, Civic Campus 1053 Carling Avenue, C409 Ottawa, ON, Canada K1Y 4E9.
    • ,
  • Michael R. Ward, PhD

      Affiliations

    • Institute of Medical Science, University of Toronto, Toronto, Canada
    • ,
  • Michael J.B. Kutryk, MD PhD

      Affiliations

    • Department of Cardiology, St Michael's Hospital, Toronto, Canada
    • ,
  • David W. Courtman, PhD

      Affiliations

    • Department of Cardiology, St Michael's Hospital, Toronto, Canada
    • Department of Surgery, St. Michael's Hospital, University of Toronto
    • ,
  • Nancy J. Camack, RN, MBA

      Affiliations

    • Clinical Research Administration, Ottawa Hospital Research Institute, Ottawa, Canada
    • ,
  • Shaun G. Goodman, MD, MSc

      Affiliations

    • Division of Cardiology, Canadian Heart Research Centre and Terrence Donnelly Heart Centre, St. Michael's Hospital, University of Toronto, Toronto, Canada
    • ,
  • Thomas G. Parker, MD

      Affiliations

    • Department of Cardiology, St Michael's Hospital, Toronto, Canada
    • ,
  • Alexander J. Dick, MD

      Affiliations

    • Sunnybrook Health Sciences Centre, Toronto, Canada
    • ,
  • Jacques Galipeau, MD

      Affiliations

    • Lady Davis Institute for Medical Research and Division of Hematology/Oncology, Jewish General Hospital, Montreal, Canada
    • ,
  • Duncan J. Stewart, MD

      Affiliations

    • Ottawa Hospital Research Institute; Department of Medicine, University of Ottawa, Ottawa, Canada

Received 16 July 2009 ,Accepted 31 December 2009.

References 

  1. NHLBI and NIH . Morbidity & mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdfLast accessed March 2009
  2. Parikh NI, Gona P, Larson MG, et al. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart Study. Circulation. 2009;119:1203–1210
  3. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e1–e161
  4. Kawamoto A, Tkebuchava T, Yamaguchi J, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003;107:461–468
  5. Fuchs S, Baffour R, Zhou Y, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726–1732
  6. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001;104:1046–1052
  7. Schachinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775–2783
  8. Schachinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210–1221
  9. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–997
  10. Lipinski MJ, Biondi-Zoccai GGL, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007;50:1761–1767
  11. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29:1807–1818
  12. Granger CB, White HD, Bates ER, et al. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 1994;74:1220–1228
  13. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344–10349
  14. Kawamoto A, Gwon H, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634–637
  15. Nishida M, Li T, Hirata K, et al. Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model. Ann Thorac Surg. 2003;75:768–773
  16. Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med. 2002;3:221–225
  17. Ward MR, Thompson KA, Keith M, et al. Endothelial progenitor cells from patients with multiple coronary artery disease risk factors exhibit reduced regenerative capacity in vitro and in vivo. Circulation. 2006;114:
  18. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600
  19. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004;109:1615–1622
  20. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–E7
  21. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287–1294
  22. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141–148
  23. Knoke JD. Nonparametric analysis of covariance for comparing change in randomized studies with baseline values subject to error. Biometrics. 1991;47:523–533
  24. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343–353
  25. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288–293
  26. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol. 2005;20:547–551
  27. Sherman DL, Loscalzo J. Endothelial dysfunction and cardiovascular disease. Cardiologia. 1997;42:177–187
  28. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370–1376
  29. Guthrie SM, Curtis LM, Mames RN, et al. The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells. Blood. 2005;105:1916–1922
  30. Heiss C, Keymel S, Niesler U, et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441–1448
  31. Dzau VJ, Gnecchi M, Pachori AS, et al. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension. 2005;46:7–18
  32. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A. 2006;103:14537–14541
  33. Kudo FA, Nishibe T, Nishibe M, et al. Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Int Angiol. 2003;22:344–348
  34. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005;112:I178–I183
  35. Stamm C, Westphal B, Kleine H, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003;361:45–46
  36. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322–1328
  37. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 2004;109:1769–1775
  38. Wijelath ES, Rahman S, Murray J, et al. Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells. J Vasc Surg. 2004;39:655–660
  39. Butler EK, Desjardins J, Leong-Poi H, et al. Critical dependence on timing of cardiac injection for engraftment of endothelial progenitor cells and functional benefit post-myocardial infarction. Circulation. 2006;114:II_15
  40. Assmus B, Schächinger V, Erbs S, et al. Acute myocardial infarction activates progenitor cells in the bone marrow of patients with coronary artery disease. Circulation. 2006;114:II_739

PII: S0002-8703(10)00060-8

doi: 10.1016/j.ahj.2009.12.021

American Heart Journal
Volume 159, Issue 3 , Pages 354-360 , March 2010

Article Tools

* Image Usage & Resolution